Global Introduction of a Low-Cost Contraceptive Implant

Springer Series on Demographic Methods and Population Analysis

Volumn 33, Issue , 2014, Pages 285-306

  Rademacher, Kate H ^a   Vahdat, Heather L ^a   Dorflinger, Laneta ^a   Owen, Derek H ^a   Steiner, Markus J ^a  

^a FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

Common Technical Document; Contraceptive Implant; Good Manufacture Practice; Good Manufacture Practice Guideline; Melinda Gate Foundation

Indexed keywords

EID: 84906058965     PISSN: 18772560     EISSN: 22151990     Source Type: Book Series    
DOI: 10.1007/978-94-007-6722-5_14     Document Type: Chapter

References (56)

1. Adamchak, S. (2010). Sino-implant (II): Year 2 monitoring, learning and evaluation experience. FHI. Unpublished report.
2. Adams, K., & Beal, M. W. (2009). Implanon: A review of the literature with recommendations for clinical management. Journal of Midwifery & Women’s Health, 54(2), 142–149.
3. Barot, S. (2008). Back to basics: The rationale for increased funds for international family planning. Guttmacher Policy Review, 11, 3.
4. Bayer HealthCare. (2012, September 26). Bayer joins global initiative for better access to safe and effective contraception. Press release. http://press.healthcare.bayer.com/en/press/news-details-page.php/14732/2012-0429. Accessed Sept 2012.
5. Bertrand, J. T., Rice, J., Sullivan, T. M., & Shelton, J. (2000). Skewed method mix: A measure of quality in family planning programs. Chapel Hill: MEASURE Evaluation.
6. The Bill & Melinda Gates Foundation. (BMGF). (2013). Innovative partnership reduces cost of Bayer’s long-acting reversible contraceptive implant by more than 50 percent. Press release. February 27, 2013. http://www.gatesfoundation.org/Media-Center/Press-Releases/2013/02/Partnership-Reduces-Cost-Of-Bayers-Reversible-Contraceptive-Implant. Accessed May 2013.
7. Brett, T. (2011, May 24). Associate Director of Procurement, MSI. Interview.
8. Clinton Health Access Initiative. (2011). Regulatory approvals for ARVs: An analysis of review timelines under the US FDA, WHO PQ, and ERP (Internal report). Received via personal correspondence.
9. Coukell, A. J., & Balfour, J. A. (1998). Levonorgestrel subdermal implants: A review of contraceptive efficacy and acceptability. Drugs, 55(6), 861–887.
10. d’Arcangues, C. (2007). Worldwide use of intrauterine devices for contraception. Contraception, 75, S2–S7.
11. Engenderhealth. (2009). Respond project. Meeting national goals and people’s needs with LA/ PMs: Kenya country assessment. http://www.respond-project.org/pages/index.php
12. FHI. (2010). Zarin launch in Sierra Leone. Fact sheet. Unpublished.
13. FHI 360 (2009 and 2012). Process capability analysis reports. Unpublished.
14. Ford, N., Calmy, A., & Mills, E. J. (2011). The first decade of antiretroviral therapy in Africa. Globalization and Health, 7, 33.
15. Frost, L. J., & Reich, M. R. (2008). Access: How do good health technologies get to poor people in poor countries? Cambridge: Harvard University Press.
16. Gross, O. (2006). WHO program for prequalification of antiretroviral, antimalarial and antituber-culosis drugs. Médecine Tropicale, 66(6), 549–551.
17. Hall, P., Oehlera, J., Woo, P., et al. (2007). A study of the capability of manufacturers of generic hormonal contraceptives in lower-and middle-income countries. Contraception, 75, 311–317.
18. Harris, G. (2011, June 20). FDA confronts challenge of monitoring imports. Agency head outlines difficulties and risks of food and drug imports. The New York Times, B3. http://www.nytimes. com/2011/06/21/health/policy/21food.html
19. Hohmann, H., & Creinin, M. D. (2007). The contraceptive implant. Clinical Obstetrics and Gynecology, 50(4), 907–917.
20. Hubacher, D., & Dorflinger, L. (2012). Avoiding controversy in international provision of subdermal contraceptive implants. Contraception, 85(5), 432–433.
21. Hubacher, D., Kimani, J., Steiner, M., et al. (2007). Contraceptive implants in Kenya: Current status and future prospects. Contraception, 75(6), 468–473.
22. Issak, B. (2011, May 18). Head of the Division of Reproductive Health, Kenya Ministry of Health. Interview.
23. Jenkins, D., Taylor, D., Owen, D., & Steiner, M. (2010). Evaluation of Sino-implant (II) explants (Final report). Family Health International. Durham, NC, USA
24. Kenya National Bureau of Statistics (KNBS) and ICF Macro. (2010). Kenya demographic and health survey 2008–09. Calverton: KNBS & ICF Macro.
25. Luo, D. (2011, May 24). Independent regulatory consultant. Interview.
26. Macartney, J. (2008, September 22). China baby milk scandal spreads as sick toll rises to 13,000. Times Online. http://www.timesonline.co.uk/tol/news/world/asia/article4800458.ece
27. Mansour, D., Inki, P., & Gemzell-Danielsson, K. (2010). Efficacy of contraceptive methods: A review of the literature. The European Journal of Contraception & Reproductive Health Care, 15(1), 4–16.
28. Marie Stopes International. (2012). Impact calculator. www.mariestopes.org
29. Marie Stopes International (MSI), FHI, Pharm Access Africa, Ltd. (2010). Introducing the contraceptive Sino-implant (II) (Zarin) in Sierra Leone (Final report). Available at: http://www. k4health.org/toolkits/implants/country_experiences/sierraleone
30. Mavranezouli, I. (2009). Health economics of contraception. Best Practice & Research. Clinical Obstetrics & Gynaecology, 23 (2), 187–198.
31. Milistein, J., Costa, A., Jadhav, S., & Dhere, R. (2009). Reaching international GMP standards for vaccine production: Challenges for developing countries. Expert Review of Vaccines, 8(5), 559–566.
32. MSD. (2013). MSD and partners announce agreement to increase access to innovative contraceptive implants Implanon® and Implanon Nxt® in the poorest countries. Press release. May 2013. http://www.rhsupplies.org/fileadmin/user_upload/Announcements/MERCK_EXTERNAL_ STATEMENT_FINAL_May_2013__4_.pdf. Accessed May 2013.
33. Neukom, J., Chilambwe, J., Mkandawire, J., et al. (2011). Dedicated providers of long-acting reversible contraception: New approach in Zambia. Contraception, 83(5), 447–452.
34. Power, J., French, R., & Cowan, F. (2007). Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods of preventing pregnancy (review). Cochrane Database of Systematic Reviews, 3(3), 1–31.
35. Ramchandran, D., & Upadhyay, U. D. (2007). Implants: The next generation. Popul Rep Ser K Injectables Implants, 7, 1–19.
36. Reproductive Health Supplies Coalition (RHSC). (2011, June 24). Private and public sectors announce commitments to increase access to contraceptives. Press release. http://www. rhsupplies.org/. Accessed 13 July 2011.
37. Reproductive Health Supplies Coalition (RHSC) (2012a, February). Supply Insider. http://www. rhsupplies.org/. Accessed 7 May 2012.
38. Reproductive Health Supplies Coalition (RHSC) (2012b, November 19). Coalition-supported initiative triggers more than $15 million in savings. Press release. http://www.rhsupplies.org/. Accessed 20 Nov 2012.
39. RHInterchange. http://rhi.rhsupplies.org/rhi/index.do?locale=en_US. Accessed May 2011 and May 2013.
40. Sivin, I., Nash, H., & Waldman, S. (2002). Jadelle levonorgestrel rod implants: A summary of scientific data and lessons learned from programmatic experience. New York: The Population Council.
41. Statistics Sierra Leone, & ICF Macro. (2009). Sierra Leone demographic and health survey 2008. Calverton: Statistics Sierra Leone (SSL) and ICF Macro. Available at: http://www.measuredhs. com/pubs/pdf/FR225/FR225.pdf
42. Steiner, M. J., Lopez, L. M., Grimes, D. A., et al. (2010). Sino-implant (II) – A levonorgestrel-releasing two-rod implant: Systematic review of the randomized controlled trials. Contraception, 81, 197–201.
43. Story, L. (2007, August 2). Lead paint prompts mattel to recall 967,000 toys. The New York Times. http://www.nytimes.com/2007/08/02/business/02toy.html
44. Sullivan, T. M., Bertrand, J. T., Rice, J., & Shelton, J. D. (2006). Skewed contraceptive mix: Why it happens, why it matters. Journal of BiosocialScience, 38, 501–521.
45. Sutherland, E. G., Alaii, J., Tsui, S., et al. (2011). Contraceptive needs of female sex workers in Kenya – A cross-sectional study. The European Journal of Contraception & Reproductive Health Care, 16(3), 173–182.
46. Tumlinson, K., Steiner, M., Rademacher, K., et al. (2011). The promise of affordable implants: Is cost recovery possible in Kenya? Contraception, 83, 88–93.
47. U.S. Agency for International Development (2012, September 26). New partnership expands access to contraception for 27 million women and girls in low-income countries. Press release. http://www.usaid.gov/news-information/press-releases/new-partnership-expands-access-contraception-27-million-women-and. Accessed Sept 2012.
48. United Nations Commission on Life-Saving Commodities for Women and Children (2012, September). Commissioners’ report. http://www.everywomaneverychild.org/images/UN_ Commission_Report_September_2012_Final.pdf. Accessed Oct 2012.
49. United Nations, Department of Economic and Social Affairs, Population Division. (2011). World contraceptive use 2010. New York: United Nations. http://www.un.org/esa/population/publications/wcu2010/Main.html.
50. United Nations Population Fund (UNFPA) (2011, April). First invitation to manufacturers of reproductive health medicines to submit an Expression of Interest (EOI) for product evaluation and UNFPA Technical assessment by the Expert Review Panel (ERP) or the Internal Technical Committee. Received through personal correspondence, May 2011.
51. US FDA. (2007). Melamine pet food recall of 2007. http://www.fda.gov/animalveterinary/safetyhealth/recallswithdrawals/ucm129575.htm
52. Waning, B., Kaplan, W., King, A. C., et al. (2009). Global strategies to reduce the price of antiretroviral medicines: Evidence from transactional databases. Bulletin of the World Health Organization, 87(7), 520–528.
53. Wirtz, V. J., Forsythe, S., Valencia-Mendoza, A., et al. (2009). Factors influencing global antiretroviral procurement prices. BMC Public Health, 9(Suppl 1), S6.
54. World Health Organization. (2010, August). WHO prequalification. http://www.who.int/mediacentre/factsheets/fs278/en/index.html. Accessed Dec 2010.
55. World Health Organization. (2012). Prequalification programme. http://apps.who.int/prequal/. Accessed Nov 2012.
56. Zhou, C. (2011, June 27) Sales Manager, Shanghai Dahua Pharmaceuticals Co., Ltd. Personal correspondence.